Apogee Therapeutics is a biopharmaceutical company founded in 2017 and headquartered in Waltham, Massachusetts. The company developed monoclonal antibodies and other biologic therapeutics targeting immunology and dermatology indications. In August 2023, Amgen acquired Apogee Therapeutics for approximately $2.4 billion, integrating the company's drug candidates and pipeline into Amgen's broader therapeutic portfolio. Prior to acquisition, Apogee had established itself as a private biotech company advancing multiple clinical-stage programs.
34 open now, 7 first appeared in the last 30d, 34 in 90d.79% of open roles are reposts.
| Round | Closed | Amount | Investors |
|---|---|---|---|
| Later | Aug 2023 | $2.4B | Amgen (acquisition) |
No open roles right now.